关于我们
关于HLB
领导寄语
沿革
地位
集团
制药,生物科技
造船
生活·健康·餘暇活動
金融
事业
制药,生物科技
细胞毒性药物
靶向治疗药物
免疫疗法
特殊船舶
GRE PIPE事业
投资者关系
股价信息
公司公告
公关
IR LETTER
报刊
资料室
职业
招聘
中文
韩文
英文
home
Title + Content
主题+内容
主题
内容
探索
顺序
主题
题目
日子
139
[ESMO 2023] ‘HLB will apply for European authorization for rivoceranib this year’
admin
2023.10.23
138
Elevar Therapeutics Highlights Competitiveness of Rivoceranib at Global Healthcare Conference 2023
admin
2023.10.13
137
Pharmaceutical firm HLB plans to move to main bourse from KOSDAQ
admin
2023.09.25
136
HLB on a quest for next-generation target cancer therapy CAR-T: CEO interview
admin
2023.09.11
135
HLB "Published in the 'Lancet' results of the Phase 3 clinical trial of riboceranib"
admin
2023.07.26
134
FDA Accepts NDA for Rivoceranib Plus Camrelizumab in Unresectable HCC
admin
2023.07.18
133
HLB To Acquire PANAGENE To Strengthen Cancer Diagnosis Business Portfolio
admin
2023.06.22
132
Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward
admin
2023.06.07
131
FDA Approval Sought for Frontline Camrelizumab Plus Rivoceranib in uHCC
admin
2023.05.23
130
Elevar submits new drug application for uHCC combo therapy
admin
2023.05.23
1
2
3
4
5
6
7
8
9
10
>
>>